基于多中心异质队列的前列腺穿刺风险计算器
北美队列交叉验证AUC为75.5%,略优于PCPTRC的72.3%,但校准度和临床净获益明显更优;外部验证结果相似。结论推荐以PBCG模型替代PCPTRC。
要点
- PBCG模型纳入年龄、PSA、直肠指检、非洲裔、一级家族史和既往阴性穿刺等常规因素。
- 以10%风险阈值为界,PBCG模型每1000例可减少25次穿刺且不漏诊高级别癌。
- PBCG模型校准度与临床净获益优于PCPTRC,推荐替代后者用于穿刺结局预测。
核心结论
- PBCG模型应替代PCPTRC用于前列腺穿刺结局的预测。
研究设计与样本
- 采用多项逻辑回归基于年龄、PSA、直肠指检、非洲裔、一级家族史和既往阴性穿刺估计穿刺时Gleason评分≥7的风险。
- 通过内部交叉验证和欧洲队列外部验证比较PBCG模型与PCPTRC。
主要发现
- 北美队列交叉验证(5992次穿刺)中PBCG模型AUC为75.5%(95%CI 74.2-76.8),PCPTRC为72.3%(70.9-73.7),差异p<0.0001。
- PBCG模型的校准度和临床净获益远优于PCPTRC。
- 以10%风险阈值为界,使用PBCG模型每1000名患者可减少25次穿刺且不漏诊任何高级别癌。
关键数值与推荐
- 预测目标为穿刺时高级别前列腺癌,定义为Gleason评分≥7。
- 风险阈值10%时,PBCG模型每1000例减少25次穿刺且不漏诊高级别癌。
- 北美交叉验证AUC:PBCG 75.5%(95%CI 74.2-76.8)对比PCPTRC 72.3%(70.9-73.7),p<0.0001。
临床怎么用
- 对拟行前列腺穿刺的男性,可用PBCG模型基于常规临床因素量化高级别癌风险。
- 以10%风险阈值辅助医患共同决策,减少不必要的穿刺而不遗漏高级别癌。
- 临床预测穿刺结局时应以PBCG模型替代PCPTRC。
局限性
- 原文摘要未系统列出局限性,仅提及PCPTRC基于1990年代六针穿刺和旧分级系统。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer prediction tools provide quantitative guidance for doctor-patient decision-making regarding biopsy. The widely used online Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) utilized data from the 1990s based on six-core biopsies and outdated grading systems. OBJECTIVE: We prospectively gathered data from men undergoing prostate biopsy in multiple diverse North American and European institutions participating in the Prostate Biopsy Collaborative Group (PBCG) in order to build a state-of-the-art risk prediction tool. DESIGN, SETTING, AND PARTICIPANTS: We obtained data from 15 611 men undergoing 16 369 prostate biopsies during 2006-2017 at eight North American institutions for model-building and three European institutions for validation. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We used multinomial logistic regression to estimate the risks of high-grade prostate cancer (Gleason score ≥7) on biopsy based on clinical characteristics, including age, prostate-specific antigen, digital rectal exam, African ancestry, first-degree family history, and prior negative biopsy. We compared the PBCG model to the PCPTRC using internal cross-validation and external validation on the European cohorts. RESULTS AND LIMITATIONS: Cross-validation on the North American cohorts (5992 biopsies) yielded the PBCG model area under the receiver operating characteristic curve (AUC) as 75.5% (95% confidence interval: 74.2-76.8), a small improvement over the AUC of 72.3% (70.9-73.7) for the PCPTRC (p<0.0001). However, calibration and clinical net benefit were far superior for the PBCG model. Using a risk threshold of 10%, clinical use of the PBCG model would lead to the equivalent of 25 fewer biopsies per 1000 patients without missing any high-grade cancers. Results were similar on external validation on 10 377 European biopsies. CONCLUSIONS: The PBCG model should be used in place of the PCPTRC for prediction of prostate biopsy outcome. PATIENT SUMMARY: A contemporary risk tool for outcomes on prostate biopsy based on the routine clinical risk factors is now available for informed decision-making.
引用
- Ankerst DP, Straubinger J, Selig K, et al. A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol. 2018. PMID: 29778349. doi:10.1016/j.eururo.2018.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。